BrainsWay Smoking Addiction Treatment Study

Dr. Mark George Outlines the Clinical Study Underlying BrainsWay Treatment of Smoking Addiction

Image

Professor Mark George of the Medical University of South Carolina describes the clinical data behind BrainsWay’s FDA-clearance for short-term smoking cessation – most notably among the 168 study subjects who completed treatment, the continuous quit rate was 28.4% in the active group, compared with 11.7% in the sham group.  Dr. George also highlights the potential to expand Deep TMS technology to treat other forms of addiction.

https://www.bioworld.com/articles/497063-fda-clears-first-brain-stimulation-device-for-smoking-cessation